With a clear and specific definition of the transcriptome of dystrophin deficiency, manipulation of identified dysregulated molecules downstream of dystrophin may lead to novel ameliorative approaches for DMD. This evidence concerns the gene DMD and neuromuscular disease caused by qualitative or quantitative defects of dystrophin.